SCHEMBL8174682

SCHEMBL8174682

CCOC(=O)Cc1cn(Cc2cccc(N(C)c3c(Cl)cccc3Cl)c2)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.51
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.46
P2RX7 Q99572 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALOX5 P09917 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
HTT P42858 1/20 0.43
FNTA P49354 2/20 0.42
FNTB P49356 2/20 0.42
F2RL3 Q96RI0 1/20 0.42
ICMT O60725 2/20 0.41
HTR6 P50406 1/20 0.41
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
PLA2G2A P14555 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8178981 0.91 LMNA (0.51) LMNAALDH1A1SMN1; SMN2P2RX7NPSR1
SCHEMBL13931030 0.91 LMNA (0.53) LMNAALDH1A1SMN1; SMN2P2RX7NPSR1
SCHEMBL8174717 0.88 LMNA (0.52) LMNAALDH1A1SMN1; SMN2P2RX7NPSR1
SCHEMBL8188626 0.88 LMNA (0.67) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL13931034 0.85 ALDH1A1 (0.50) LMNAALDH1A1L3MBTL1FNTAFNTB
SCHEMBL8167250 0.82 LMNA (0.43) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8166587 0.80 CHRNB2 (0.60) LMNAALDH1A1SMN1; SMN2P2RX7NPSR1
SCHEMBL8180951 0.80 ICMT (0.41) LMNAALDH1A1SMN1; SMN2P2RX7ALOX5
SCHEMBL8187802 0.80 FNTA (0.59) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8180735 0.79 LMNA (0.66) LMNAALDH1A1SMN1; SMN2NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS LMNA 2969/4885ALDH1A1 1836/4885SMN1; SMN2 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.